InvivoSciences® and Myomics Announce Partnership

InvivoSciences, LLC (IVS) and Myomics, Inc. (Providence, RI) announce a corporate partnership to provide high content compound screening services using 3D engineered tissue. Both Myomics and IVS have pioneered and perfected their technologies to mass-produce and assay miniaturized engineered human and animal tissues in standardized 96- and 384- well formats. Using their combined rich portfolio of technologies, the companies profile compounds that improve or impair physiology of tissues, including skeletal muscle, cardiac muscle and connective tissues, by automatically measuring their mechanical, contractile, and biological properties. In addition, these technologies provide comprehensive toxicity assessment of compounds. We offer a unique competitive advantage for our customers to develop products based on the best available physiological information for new drug discovery and product development for human and animal applications. The mission of both companies is to improve human health by enabling discovery and development of new therapeutics, with a focus on diseases with limited treatment options such as muscular dystrophy, scleroderma, lupus, and cardiac fibrosis.

“We’re pleased to combine the strength of our synergistic technologies, developed independently to satisfy the increased demand for compound screening systems that can predict a drug candidate’s actions on human tissues”, said Ayla Annac, co-founder and CEO of IVS.

Herman Vandenburgh, cofounder and CEO of Myomics agreed: “We believe that the services that we provide based on this partnership will have a profound positive impact on drug discovery by predicting efficacy and safety of compounds in the early stage of drug development using complex human tissue models. This will result in reduced late-stage attrition.”

About InvivoSciences, LLC: InvivoSciences, LLC, established in 2001, creates, manufactures and markets tools for three dimensional (3D) cell culture systems and provides compound screening services with them. Palpator TM is a robotic mechanical profiler for ultra-soft materials, such as biological tissues and engineered tissue constructs of various types including human engineered heart tissues. The tissue culture tools developed by IVS, MicroChamber- 8 TM (MC-8 TM) and IVS InsertsTM , enable fabrication, growth, assay and storage of engineered tissue constructs without removing them from wells. With a mechanical conditioning device, Tissue StretcherTM, tissue constructs can be cultured under repetitive mechanical stimuli. IVS has been successfully providing contract research services to identify lead compounds and novel product benefits for pharmaceutical, cosmetic, biotech, food, and chemical companies. www.invivosciences.com

About Myomics, Inc.: Myomics, Inc. was incorporated in Rhode Island in 2003. The company’s robotic MyoForce Analysis System™ (MFAS™) uses contractile three-dimensional human or mouse skeletal muscle, cardiac muscle, and smooth muscle tissue analogs to rapidly screen drugs in vitro for modified muscle strength, altered fatigue rates, and contraction-induced injury prevention. The company’s core technology (drug screening using three dimensional contractile skeletal muscle-based platforms) has been successfully implemented to provide compound screening services for pharmaceutical companies including Novartis Pharma AG and Pfizer, as well as numerous academic centers, and not-for-profit foundations. Several positive hits are currently in clinical trials. www.myomics.com

Winners of the 2009 Biotechnology Vision Summit’s Emerging Company Showcase announced

Six Wisconsin biotechnology companies have been selected the winners of the first Emerging Company Showcase. The showcase is part of the Biotechnology Vision Summit 2009, being held on Wednesday, Oct. 7, at the Madison Marriott West in Madison, Wis. The summit and the showcase are being hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s biotechnology industry.

The companies, each of which has been in business four years or less, were chosen because they have transitioned successfully out of the laboratory, with good proof of concept for their products. All of the winners are at the pre-commercialization stage, but have made progress towards bringing their products to market. Each was judged to have a unique value proposition.. This year’s Emerging Company Showcase winners are:

  • AquaMost LLC, Madison, Wis., has created a unique, scalable water-purification device that destroys a wide variety of contaminants and pathogens. The company’s product will enable it to address significant unmet needs in a $1.5-billion market.
  • Echometrix LLC, Madison, Wis., is a developer of a proprietary ultrasound technology, licensed from the Wisconsin Alumni Research Foundation, that offers a new quantitative approach to the functional analysis of musculoskeletal injuries.
  • Flex Biomedical Inc., Madison, Wis., is developing and commercializing novel products for the treatment and diagnosis of orthopedic injuries and diseases, including a synthetic joint-lubricating polymer, Flex Polymer, and a novel osteoarthritis diagnostic, Flex qCTA.
  • Invivosciences LLC, Wauwatosa, Wis., is researching and developing engineered, tissue-based tests and products that mimic human and animal functions. Its high-throughput platform technology, supported by the Palpator™ and Mini-Construct Chamber™, enables actionable, personalized diagnostics, toxicology studies, drug screening and development using human cell-based tissue models.
  • Rapid Diagnostek Inc., Hudson, Wis., has developed a patented biosensor platform that offers one-step, 60-second, high-sensitivity detection of pathogens, proteins and bio-molecules in blood, urine and other liquids, without reagents and using a low-cost, cell-phone-sized instrument.
  • Semba Biosciences Inc., Madison, Wis., provides instruments and consumables for chemical and biological compound purification, and contract purification services. The company’s chromatography system is a fully-automated, bench-top-deployable, continuous flow system for research and semi-preparative scale purification.

In addition to complementary registration for the summit, the winners receive high-visibility exhibit space, recognition at one of its large plenary sessions and other premiums.

“We are delighted to recognize the first six participants in BioForward’s Emerging Company Showcase,” said Bryan Z. Renk, executive director of BioForward. “Together, these six companies represent the breadth and depth of innovative companies that continue to emerge in Wisconsin’s growing biotechnology industry.”

Contract Research Organization for Drug Discovery